05/15/2017
Anapharm Europe Announces Rebranding & Laboratory Expansion
We are pleased to announce that as part of our rebranding strategy, our brand name has now changed from Anapharm Europe to Anapharm Bioanalytics.
Our rebranding project is built on many improvements we have made to our services as well as on the international growth of our business. We have recently completed the expansion of our facilities in Barcelona increasing our lab space by 50%, acquired two additional ABSciex 6500 LC-MS/MS/UPLC platforms, upgraded software and hired additional staff in order to offer our clients increased capacity and improved study timelines for both small and large molecule bioanalysis.
The name change does not affect the legal personality of the existing entity (namely Anapharm Europe S.L.U.) which retains its rights and obligations in all existing legal relationships with third parties as well as the regulatory track record achieved to date including GLP and ANVISA certifications as well as FDA and EU-GCP inspection history.
What it means for our clients is that it is business as usual. We will continue to execute projects with the same, if not better, level of excellence and quality standards you have come to experience.
Our e-mail addresses will change but our phone numbers and headquarter’s address will remain the same. You can continue to connect with us online at our new website www.anapharmbioanalytics.com.
We take this opportunity to thank all our valued clients for their continued trust and look forward to delivering great value services that meet your expectations time after time.
MORE NEWS
Webinar #1: Navigating Bioanalytical Challenges: from Small Molecules to Complex Peptides
In this 30-minute on-demand webinar, discover practical strategies to troubleshoot common analytical challenges, from small molecules to complex peptides, illustrated with real case studies from our laboratory.
Anti-PEG Antibodies: How Advanced Immunogenicity Testing Overcomes Detection Challenges
Detecting anti-PEG antibodies in clinical immunogenicity testing of PEGylated therapeutics presents unique bioanalytical challenges: from PEG’s repetitive structure causing low signal-to-noise ratios in standard assay formats, to selecting appropriate positive controls and distinguishing anti-drug from anti-PEG antibodies. This blog describes how the bioanalytical team at Anapharm Bioanalytics addressed these challenges during the development and validation of an immunogenicity assay using the Affinity Capture Elution–AGL (ACE-AGL) MSD immunoassay format.
Protein Digestion for LC-MS Bioanalysis: Comparing Standard and Kit-Based Methods
Quantitative bioanalysis of therapeutic proteins via liquid chromatography–mass spectrometry (LC-MS) typically relies on the analysis of surrogate peptides rather than intact proteins. Selecting the right digestion method impacts sensitivity, reproducibility, and cost. This blog compares three approaches tested in-house at Anapharm: standard trypsin digestion, the use of a kit with a thermostable immobilized trypsin, and a kit with ready-to-use reagents.